LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox
Masayuki Saijo, Yasushi Ami, Yuriko Suzaki, Noriyo Nagata, Naoko Iwata, Hideki Hasegawa, Momoko Ogata, Shuetsu Fukushi, Tetsuya Mizutani, Tetsutaro Sata, Takeshi Kurata, Ichiro Kurane, Shigeru Morikawa, Masayuki Saijo, Yasushi Ami, Yuriko Suzaki, Noriyo Nagata, Naoko Iwata, Hideki Hasegawa, Momoko Ogata, Shuetsu Fukushi, Tetsuya Mizutani, Tetsutaro Sata, Takeshi Kurata, Ichiro Kurane, Shigeru Morikawa
Abstract
The potential threat of smallpox as a bioweapon has led to the production and stockpiling of smallpox vaccine in some countries. Human monkeypox, a rare but important viral zoonosis endemic to central and western Africa, has recently emerged in the United States. Thus, even though smallpox has been eradicated, a vaccinia virus vaccine that can induce protective immunity against smallpox and monkeypox is still invaluable. The ability of the highly attenuated vaccinia virus vaccine strain LC16m8, with a mutation in the important immunogenic membrane protein B5R, to induce protective immunity against monkeypox in nonhuman primates was evaluated in comparison with the parental Lister strain. Monkeys were immunized with LC16m8 or Lister and then infected intranasally or subcutaneously with monkeypox virus strain Liberia or Zr-599, respectively. Immunized monkeys showed no symptoms of monkeypox in the intranasal-inoculation model, while nonimmunized controls showed typical symptoms. In the subcutaneous-inoculation model, monkeys immunized with LC16m8 showed no symptoms of monkeypox except for a mild ulcer at the site of monkeypox virus inoculation, and those immunized with Lister showed no symptoms of monkeypox, while nonimmunized controls showed lethal and typical symptoms. These results indicate that LC16m8 prevents lethal monkeypox in monkeys, and they suggest that LC16m8 may induce protective immunity against smallpox.
Figures
References
- Cassimatis, D. C., J. E. Atwood, R. M. Engler, P. E. Linz, J. D. Grabenstein, and M. N. Vernalis. 2004. Smallpox vaccination and myopericarditis: a clinical review. J. Am. Coll. Cardiol. 43:1503-1510.
- CDC. 2004. Update: adverse events following civilian smallpox vaccination—United States, 2003. Morb. Mortal. Wkly. Rep. 53:106-107.
- Chen, N., G. Li, M. K. Liszewski, J. P. Atkinson, P. B. Jahrling, Z. Feng, J. Schriewer, C. Buck, C. Wang, E. J. Lefkowitz, J. J. Esposito, T. Harms, I. K. Damon, R. L. Roper, C. Upton, and R. M. Buller. 2005. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340:46-63.
- Chen, R. T., and J. M. Lane. 2003. Myocarditis: the unexpected return of smallpox vaccine adverse events. Lancet 362:1345-1346.
- Cohen, J. 2002. Public health. Looking for vaccines that pack a wallop without the side effects. Science 298:2314.
- Di Giulio, D. B., and P. B. Eckburg. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4:15-25.
- Esposito, J. J., and F. Fenner. 2001. Poxviruses, p. 2887-2921. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, Pa.
- Galmiche, M. C., J. Goenaga, R. Wittek, and L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254:71-80.
- Guarner, J., B. J. Johnson, C. D. Paddock, W. J. Shieh, C. S. Goldsmith, M. G. Reynolds, I. K. Damon, R. L. Regnery, and S. R. Zaki. 2004. Monkeypox transmission and pathogenesis in prairie dogs. Emerg. Infect. Dis. 10:426-431.
- Halsell, J. S., J. R. Riddle, J. E. Atwood, P. Gardner, R. Shope, G. A. Poland, G. C. Gray, S. Ostroff, R. E. Eckart, D. R. Hospenthal, R. L. Gibson, J. D. Grabenstein, M. K. Arness, and D. N. Tornberg. 2003. Myopericarditis following smallpox vaccination among vaccinia-naïve US military personnel. JAMA 289:3283-3289.
- Hashizume, S., H. Yoshizawa, M. Morita, and K. Suzuki. 1985. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain, p. 88-99. In G. V. Quinnan (ed.), Vaccinia viruses as vectors for vaccine antigens. Elsevier, Amsterdam, The Netherlands.
- Hatakeyama, S., K. Moriya, M. Saijo, Y. Morisawa, I. Kurane, K. Koike, S. Kimura, and S. Morikawa. 2005. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations. Clin. Diagn. Lab. Immunol. 12:520-524.
- Hollinshead, M., G. Rodger, H. Van Eijl, M. Law, R. Hollinshead, D. J. Vaux, and G. L. Smith. 2001. Vaccinia virus utilizes microtubules for movement to the cell surface. J. Cell Biol. 154:389-402.
- Hooper, J. W., D. M. Custer, and E. Thompson. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181-195.
- Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433-4443.
- Hu, G., M. J. Wang, M. J. Miller, G. N. Holland, D. A. Bruckner, R. Civen, L. A. Bornstein, L. Mascola, M. A. Lovett, B. J. Mondino, and D. A. Pegues. 2004. Ocular vaccinia following exposure to a smallpox vaccinee. Am. J. Ophthalmol. 137:554-556.
- Katz, E., B. M. Ward, A. S. Weisberg, and B. Moss. 2003. Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein. J. Virol. 77:12266-12275.
- Khodakevich, L., Z. Jezek, and D. Messinger. 1988. Monkeypox virus: ecology and public health significance. Bull. W. H. O. 66:747-752.
- Kidokoro, M., M. Tashiro, and H. Shida. 2005. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl. Acad. Sci. USA 102:4152-4157.
- Kimura, M., and H. Sakai. 1996. Complications of smallpox vaccination. Clin. Virol. 24:30-39.
- Kitamura, T. 1999. Smallpox eradication and future prospect of smallpox vaccine. Clin. Virol. 27:378-384.
- Lane, J. M., and J. Goldstein. 2003. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis. 14:189-195.
- Miller, J. R., N. M. Cirino, and E. F. Philbin. 2003. Generalized vaccinia 2 days after smallpox revaccination. Emerg. Infect. Dis. 9:1649-1650.
- Morikawa, S., T. Sakiyama, H. Hasegawa, M. Saijo, A. Maeda, I. Kurane, G. Maeno, J. Kimura, C. Hirama, T. Yoshida, Y. Asahi-Ozaki, T. Sata, T. Kurata, and A. Kojima. 2005. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J. Virol. 79:11873-11891.
- Murphy, J. G., R. S. Wright, G. K. Bruce, L. M. Baddour, M. A. Farrell, W. D. Edwards, H. Kita, and L. T. Cooper. 2003. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet 362:1378-1380.
- Nagata, N., T. Iwasaki, Y. Ami, A. Harashima, I. Hatano, Y. Suzaki, K. Yoshii, T. Yoshii, A. Nomoto, and T. Kurata. 2001. Comparison of neuropathogenicity of poliovirus type 3 in transgenic mice bearing the poliovirus receptor gene and cynomolgus monkeys. Vaccine 19:3201-3208.
- Nagata, N., H. Shimizu, Y. Ami, Y. Tano, A. Harashima, Y. Suzaki, Y. Sato, T. Miyamura, T. Sata, and T. Iwasaki. 2002. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J. Med. Virol. 67:207-216.
- Neubauer, H., U. Reischl, S. Ropp, J. J. Esposito, H. Wolf, and H. Meyer. 1998. Specific detection of monkeypox virus by polymerase chain reaction. J. Virol. Methods 74:201-207.
- Newsome, T. P., N. Scaplehorn, and M. Way. 2004. SRC mediates a switch from microtubule- to actin-based motility of vaccinia virus. Science 306:124-129.
- Reed, K. D., J. W. Melski, M. B. Graham, R. L. Regnery, M. J. Sotir, M. V. Wegner, J. J. Kazmierczak, E. J. Stratman, Y. Li, J. A. Fairley, G. R. Swain, V. A. Olson, E. K. Sargent, S. C. Kehl, M. A. Frace, R. Kline, S. L. Foldy, J. P. Davis, and I. K. Damon. 2004. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350:342-350.
- Saurina, G., S. Shirazi, J. M. Lane, B. Daniel, and L. DiEugenia. 2003. Myocarditis after smallpox vaccination: a case report. Clin. Infect. Dis. 37:145-146.
- Schmelz, M., B. Sodeik, M. Ericsson, E. J. Wolffe, H. Shida, G. Hiller, and G. Griffiths. 1994. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J. Virol. 68:130-147.
- Semba, R. D. 2003. The ocular complications of smallpox and smallpox immunization. Arch. Ophthalmol. 121:715-719.
- Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
- Takahashi-Nishimaki, F., S. Funahashi, K. Miki, S. Hashizume, and M. Sugimoto. 1991. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology 181:158-164.
- Takahashi-Nishimaki, F., K. Suzuki, M. Morita, T. Maruyama, K. Miki, S. Hashizume, and M. Sugimoto. 1987. Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination. J. Gen. Virol. 68:2705-2710.
- Weltzin, R., J. Liu, K. V. Pugachev, G. A. Myers, B. Coughlin, P. S. Blum, R. Nichols, C. Johnson, J. Cruz, J. S. Kennedy, F. A. Ennis, and T. P. Monath. 2003. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9:1125-1130.
- Whitman, T. J., M. A. Ferguson, and C. F. Decker. 2003. Cardiac dysrhythmia following smallpox vaccination. Clin. Infect. Dis. 37:1579-1580.
- Zaucha, G. M., P. B. Jahrling, T. W. Geisbert, J. R. Swearengen, and L. Hensley. 2001. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Investig. 81:1581-1600.
Source: PubMed